Biotech Bay
Filter News
Found 65,746 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting
12/5/2020
Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: “Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study,” presented by Dr. Nina Khanna of the University Hospital of Basel, Switzerland,
-
Like the Grinch’s heart at Christmas, the Nasdaq Exchange grew a little bigger this week with multiple life science companies raising hundreds of millions of dollars in initial public offerings.
-
As the dose of Sutro Biopharma’s ovarian cancer drug, STRO-002, increased in an ongoing Phase I dose-escalation trial, survival rates have also increased.
-
New CRISPR-Based Test for COVID-19 Uses a Smartphone Camera
12/4/2020
Imagine swabbing your nostrils, putting the swab in a device, and getting a read-out on your phone in 15 to 30 minutes that tells you if you are infected with the COVID-19 virus
-
Anpac Bio Announces Change of Auditor
12/4/2020
Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today the resignation of Ernst & Young Hua Ming LLP ("EY"), which previously was the independent registered public accounting firm of Anpac Bio, on November 3, 2020 and the appointment of Friedman LLP ("Friedman") as the Company's independ
-
AcelRx Pharmaceuticals Announces Partnership with the National Rural Health Association
12/4/2020
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a partnership with the National Rural Health Association (NRHA) focused on the co-development and execution of a strategic marketing plan to educate and promote DSUVIA
-
Centers for Medicare & Medicaid Services Creates New Codes That Establish Specific Payment for Intravascular Lithotripsy Performed Below the KneeFour New C-Codes for IVL Performed Below the Knee in Hospital Outpatient Setting
12/4/2020
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified peripheral and coronary artery disease, announced today that as part of the calendar year 2021 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule, the Centers for Medicare & Medicaid Services (CMS) has created four new codes for IVL procedures performed in the ti
-
Amgen and McKesson Launch Strategic Agreement to Advance Cancer Innovation in Communities
12/4/2020
McKesson and Amgen (NASDAQ:AMGN), one of the world’s leading biotechnology companies, have signed a strategic agreement to help improve cancer care in community oncology settings
-
Cortexyme’s Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer’s Disease Successfully Advances Past Interim Analysis
12/4/2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced that the independent Data Monitoring Committee (DMC) conducted a pre-planned interim analysis and recommended Cortexyme continue the Phase 2/3 GAIN Trial of atuzaginstat (COR388) as planned to the 1-year endpoint.
-
Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Fifth Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020
12/4/2020
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc., (collectively, the "Company") have jointly entered into a fifth amendment to the accounts receivable purchase agreement with Oasis Capital, LLC ("Oasis"),
-
Avinger Expands Tigereye(TM) Limited Launch
12/4/2020
Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today provided an update on the limited launch of its Tigereye™ next generation image-guided chronic total occlusion (CTO) crossing system
-
Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition
12/4/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be presented in two poster presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held virtually December 5-8, 2020.
-
Penumbra, Inc. to Participate in CEO Discussion with Bank of America
12/4/2020
Penumbra, Inc. (NYSE: PEN) today announced that its chief executive officer is scheduled to participate in a discussion with Bank of America on Tuesday, December 8, 2020.
-
Momentus Inc. to Participate at the Truist Securities Industrials and Services Summit
12/4/2020
Momentus Inc. (“Momentus”), a commercial space company offering in-space infrastructure services, today announced it will participate at the Truist Securities Industrials and Services Summit on Tuesday, December 8, 2020.
-
Pulse Biosciences Presents Update on Nano-Pulse Stimulation™ Technology at Prestigous Energy-Based Devices and Aesthetic Dermatology Conference
12/4/2020
Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that a scientific update on its non-thermal NPS mechanism will be featured at the upcoming Controversies and Conversations in Lasers & Cosmetic Surgery Symposium.
-
As if attempting to steal hard-won research wasn’t bad enough, hackers are now hitting people where it really hurts – with e-documents containing malicious code embedded in false offers of employment.
-
Therapies developed using E3 ligase proteins will get a potent infusion, as AbbVie combines its commercialization expertise with Frontier Medicine’s proprietary chemoproteomics platform to develop potentially efficacious therapies for difficult-to-drug protein targets.
-
I Peace, Inc. Obtains IRB Approval for Production of Clinical and Research-Grade iPSCs for Commercial Use
12/3/2020
I Peace, Inc., a Palo Alto-based biotech start-up focusing on Nobel Prize-winning induced pluripotent stem cell (iPSC) technology obtains approval from an independent Institutional Review Board (IRB) for the process of generating iPSCs—including donor recruiting, screening, blood draw, iPSC generation, storage, and distribution—for commercial use.
-
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12/3/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today provided a clinical update from the company's ongoing dose-escalation Phase 1 study of STRO-002